Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%

Comparison 12: SNRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 12: SNRIs showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.3 [0.85, 1.99]
4 studies · 1173 participants
Low

Comparison 12: SNRIs vs placebo

Withdrawals due to adverse events · adults with SAnD

Comparison 12: SNRIs probably leads to higher dropouts due to adverse events (acute phase) compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 3.23 [2.15, 4.86]
4 studies · 1213 participants
Moderate

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 902 participants
Moderate

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 261 participants
Low

Comparison 12: SNRIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 261 participants
Low

Comparison 12: SNRIs vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.98 [0.88, 1.1]
2 studies · 687 participants
Very low

Comparison 12: SNRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found